Budesonide in grass pollen rhinitis

Philip S. Norman, Peter Socrates Creticos, R. Tobey, D. G. Proud, A. Kagey-Sobotka, D. A. Meyers, T. Persson

Research output: Contribution to journalArticle

Abstract

To determine the relative efficacy, to compare the incidence of adverse experiences, and to assess the systemic glucocorticoid effect of nasal preparations of budesonide, 200 μg bid, and placebo, 50 adult patients with seasonal allergic rhinitis due to grass pollen were studied in a stratified, double-blind parallel group design. After a 2-week baseline period, budesonide nasal spray, 100 μg per nostril twice a day, was compared with placebo nasal spray over a 4-week treatment period. Supplementary treatment with chlorpheniramine, 4-mg tablets, was permitted when necessary to control symptoms. Daily symptom and medication diaries were kept by the patients. Investigator assessments of symptoms and side effects were made at clinic visits at 2-week intervals. At baseline and again towards the end of the study, blood samples were drawn for the determination of plasma cortisol levels and 24-hour urine samples collected for the measurement of 17- hydroxycorticosteroid output. Of the 24 men and 26 women entering, 49 completed the study. Symptom scores for sneezing, stuffy nose, and nasal secretion all decreased dramatically from baseline when budesonide treatment was started. The decrease in symptoms was greater for budesonide than for placebo (P <.001). There was no difference between budesonide and placebo with regard to eye itch and rescue medication used. Morning nasal washes were taken during the grass season before treatment was started and 16 to 17 days after. They showed a significant decrease in TAME esterase levels in secretions in the budesonide treated patients (P = .03) but not in the placebo-treated patients. Paradoxically, histamine levels in secretions were increased significantly (P = .0004) in budesonide-treated patients. Investigator assessment found no difference between budesonide and placebo upon physical examination of the nose. No significant differences were found between baseline and end of treatment values for plasma cortisol or urinary 17-hydroxycorticosteroid levels for either study group, nor were there significant differences found between the groups. Budesonide controlled the nasal symptoms of seasonal allergic rhinitis better than placebo but did not decrease endogenous cortisol levels compared with placebo.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalAnnals of Allergy
Volume69
Issue number4
StatePublished - 1992

Fingerprint

Budesonide
Rhinitis
Pollen
Poaceae
Nose
Placebos
17-Hydroxycorticosteroids
Nasal Sprays
Hydrocortisone
Seasonal Allergic Rhinitis
Research Personnel
Chlorpheniramine
Sneezing
Therapeutics
Symptom Assessment
Ambulatory Care
Histamine
Glucocorticoids
Tablets
Physical Examination

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Norman, P. S., Creticos, P. S., Tobey, R., Proud, D. G., Kagey-Sobotka, A., Meyers, D. A., & Persson, T. (1992). Budesonide in grass pollen rhinitis. Annals of Allergy, 69(4), 309-316.

Budesonide in grass pollen rhinitis. / Norman, Philip S.; Creticos, Peter Socrates; Tobey, R.; Proud, D. G.; Kagey-Sobotka, A.; Meyers, D. A.; Persson, T.

In: Annals of Allergy, Vol. 69, No. 4, 1992, p. 309-316.

Research output: Contribution to journalArticle

Norman, PS, Creticos, PS, Tobey, R, Proud, DG, Kagey-Sobotka, A, Meyers, DA & Persson, T 1992, 'Budesonide in grass pollen rhinitis', Annals of Allergy, vol. 69, no. 4, pp. 309-316.
Norman PS, Creticos PS, Tobey R, Proud DG, Kagey-Sobotka A, Meyers DA et al. Budesonide in grass pollen rhinitis. Annals of Allergy. 1992;69(4):309-316.
Norman, Philip S. ; Creticos, Peter Socrates ; Tobey, R. ; Proud, D. G. ; Kagey-Sobotka, A. ; Meyers, D. A. ; Persson, T. / Budesonide in grass pollen rhinitis. In: Annals of Allergy. 1992 ; Vol. 69, No. 4. pp. 309-316.
@article{d334d867ec0c4e60a2f3ff9ab3b338e8,
title = "Budesonide in grass pollen rhinitis",
abstract = "To determine the relative efficacy, to compare the incidence of adverse experiences, and to assess the systemic glucocorticoid effect of nasal preparations of budesonide, 200 μg bid, and placebo, 50 adult patients with seasonal allergic rhinitis due to grass pollen were studied in a stratified, double-blind parallel group design. After a 2-week baseline period, budesonide nasal spray, 100 μg per nostril twice a day, was compared with placebo nasal spray over a 4-week treatment period. Supplementary treatment with chlorpheniramine, 4-mg tablets, was permitted when necessary to control symptoms. Daily symptom and medication diaries were kept by the patients. Investigator assessments of symptoms and side effects were made at clinic visits at 2-week intervals. At baseline and again towards the end of the study, blood samples were drawn for the determination of plasma cortisol levels and 24-hour urine samples collected for the measurement of 17- hydroxycorticosteroid output. Of the 24 men and 26 women entering, 49 completed the study. Symptom scores for sneezing, stuffy nose, and nasal secretion all decreased dramatically from baseline when budesonide treatment was started. The decrease in symptoms was greater for budesonide than for placebo (P <.001). There was no difference between budesonide and placebo with regard to eye itch and rescue medication used. Morning nasal washes were taken during the grass season before treatment was started and 16 to 17 days after. They showed a significant decrease in TAME esterase levels in secretions in the budesonide treated patients (P = .03) but not in the placebo-treated patients. Paradoxically, histamine levels in secretions were increased significantly (P = .0004) in budesonide-treated patients. Investigator assessment found no difference between budesonide and placebo upon physical examination of the nose. No significant differences were found between baseline and end of treatment values for plasma cortisol or urinary 17-hydroxycorticosteroid levels for either study group, nor were there significant differences found between the groups. Budesonide controlled the nasal symptoms of seasonal allergic rhinitis better than placebo but did not decrease endogenous cortisol levels compared with placebo.",
author = "Norman, {Philip S.} and Creticos, {Peter Socrates} and R. Tobey and Proud, {D. G.} and A. Kagey-Sobotka and Meyers, {D. A.} and T. Persson",
year = "1992",
language = "English (US)",
volume = "69",
pages = "309--316",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - Budesonide in grass pollen rhinitis

AU - Norman, Philip S.

AU - Creticos, Peter Socrates

AU - Tobey, R.

AU - Proud, D. G.

AU - Kagey-Sobotka, A.

AU - Meyers, D. A.

AU - Persson, T.

PY - 1992

Y1 - 1992

N2 - To determine the relative efficacy, to compare the incidence of adverse experiences, and to assess the systemic glucocorticoid effect of nasal preparations of budesonide, 200 μg bid, and placebo, 50 adult patients with seasonal allergic rhinitis due to grass pollen were studied in a stratified, double-blind parallel group design. After a 2-week baseline period, budesonide nasal spray, 100 μg per nostril twice a day, was compared with placebo nasal spray over a 4-week treatment period. Supplementary treatment with chlorpheniramine, 4-mg tablets, was permitted when necessary to control symptoms. Daily symptom and medication diaries were kept by the patients. Investigator assessments of symptoms and side effects were made at clinic visits at 2-week intervals. At baseline and again towards the end of the study, blood samples were drawn for the determination of plasma cortisol levels and 24-hour urine samples collected for the measurement of 17- hydroxycorticosteroid output. Of the 24 men and 26 women entering, 49 completed the study. Symptom scores for sneezing, stuffy nose, and nasal secretion all decreased dramatically from baseline when budesonide treatment was started. The decrease in symptoms was greater for budesonide than for placebo (P <.001). There was no difference between budesonide and placebo with regard to eye itch and rescue medication used. Morning nasal washes were taken during the grass season before treatment was started and 16 to 17 days after. They showed a significant decrease in TAME esterase levels in secretions in the budesonide treated patients (P = .03) but not in the placebo-treated patients. Paradoxically, histamine levels in secretions were increased significantly (P = .0004) in budesonide-treated patients. Investigator assessment found no difference between budesonide and placebo upon physical examination of the nose. No significant differences were found between baseline and end of treatment values for plasma cortisol or urinary 17-hydroxycorticosteroid levels for either study group, nor were there significant differences found between the groups. Budesonide controlled the nasal symptoms of seasonal allergic rhinitis better than placebo but did not decrease endogenous cortisol levels compared with placebo.

AB - To determine the relative efficacy, to compare the incidence of adverse experiences, and to assess the systemic glucocorticoid effect of nasal preparations of budesonide, 200 μg bid, and placebo, 50 adult patients with seasonal allergic rhinitis due to grass pollen were studied in a stratified, double-blind parallel group design. After a 2-week baseline period, budesonide nasal spray, 100 μg per nostril twice a day, was compared with placebo nasal spray over a 4-week treatment period. Supplementary treatment with chlorpheniramine, 4-mg tablets, was permitted when necessary to control symptoms. Daily symptom and medication diaries were kept by the patients. Investigator assessments of symptoms and side effects were made at clinic visits at 2-week intervals. At baseline and again towards the end of the study, blood samples were drawn for the determination of plasma cortisol levels and 24-hour urine samples collected for the measurement of 17- hydroxycorticosteroid output. Of the 24 men and 26 women entering, 49 completed the study. Symptom scores for sneezing, stuffy nose, and nasal secretion all decreased dramatically from baseline when budesonide treatment was started. The decrease in symptoms was greater for budesonide than for placebo (P <.001). There was no difference between budesonide and placebo with regard to eye itch and rescue medication used. Morning nasal washes were taken during the grass season before treatment was started and 16 to 17 days after. They showed a significant decrease in TAME esterase levels in secretions in the budesonide treated patients (P = .03) but not in the placebo-treated patients. Paradoxically, histamine levels in secretions were increased significantly (P = .0004) in budesonide-treated patients. Investigator assessment found no difference between budesonide and placebo upon physical examination of the nose. No significant differences were found between baseline and end of treatment values for plasma cortisol or urinary 17-hydroxycorticosteroid levels for either study group, nor were there significant differences found between the groups. Budesonide controlled the nasal symptoms of seasonal allergic rhinitis better than placebo but did not decrease endogenous cortisol levels compared with placebo.

UR - http://www.scopus.com/inward/record.url?scp=0026440858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026440858&partnerID=8YFLogxK

M3 - Article

C2 - 1416266

AN - SCOPUS:0026440858

VL - 69

SP - 309

EP - 316

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -